Literature DB >> 7260838

Intraarterial infusion chemotherapy for hepatic carcinoma using a totally implantable infusion pump.

H Buchwald, T B Grage, P P Vassilopoulos, T D Rohde, R L Varco, P J Blackshear.   

Abstract

Intraarterial infusion chemotherapy has several theoretical advantage over conventional therapy for the treatment of unresectable malignancies. However, the catheter problems and patient restriction to the hospital associated with its use have resulted in infrequent application and a notable lack of progress in this field of oncology. This paper describes the use of a totally implantable, percutaneously refillable infusion pump in 5 patients with primary or metastatic carcinoma of the liver. The infusion cannulae were placed into the hepatic arteries under direct vision at laparotomy, and the pumps were placed in subcutaneous pockets. Four patients received infusions of 5-fluorodeoxyuridine at rates of 0.2-0.5 mg/kg/day for periods of three to 29 weeks; the pump in the fifth patient was defective and was removed. The implanted pumps were well tolerated in these subjects, who received chemotherapy as outpatients; the only adverse effects noted were related to FUDR toxicity. This implantable infusion pump appears to be a practical means of delivering long-term intraarterial infusion chemotherapy to outpatients.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7260838     DOI: 10.1002/1097-0142(19800301)45:5<866::aid-cncr2820450507>3.0.co;2-3

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  23 in total

1.  Hepatic arterial infusion after curative resection of colorectal cancer metastases: a meta-analysis of prospective clinical trials.

Authors:  Thomas E Clancy; Elijah Dixon; Roy Perlis; Francis R Sutherland; Michael J Zinner
Journal:  J Gastrointest Surg       Date:  2005-02       Impact factor: 3.452

2.  Drug delivery by program or sensor controlled infusion devices.

Authors:  M Franetzki
Journal:  Pharm Res       Date:  1984-11       Impact factor: 4.200

3.  Primary hepatocellular carcinoma--recent advances and future prospects.

Authors: 
Journal:  West J Med       Date:  1985-10

Review 4.  Hepatic arterial infusional chemotherapy in the management of colorectal cancer liver metastases.

Authors:  Alexandre Doussot; Nancy E Kemeny; Michael I D'Angelica
Journal:  Hepat Oncol       Date:  2015-07-27

5.  A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases.

Authors:  A E Chang; P D Schneider; P H Sugarbaker; C Simpson; M Culnane; S M Steinberg
Journal:  Ann Surg       Date:  1987-12       Impact factor: 12.969

6.  A pharmacokinetic study of adriamycin and 4'epi-adriamycin after simultaneous intra-arterial liver administration.

Authors:  S Eksborg; M Andersson; L Domellöf; U Lönroth
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

7.  Intrahepatic and intravenous administration of adriamycin--a comparative pharmacokinetic study in patients with malignant liver tumours.

Authors:  S Eksborg; B J Cedermark; H S Strandler
Journal:  Med Oncol Tumor Pharmacother       Date:  1985

8.  Primary and metastatic liver lesions of clinical colorectal cancer differ in chemosensitivity.

Authors:  Y Maehara; Y Sakaguchi; Y Emi; T Kusumoto; S Kohnoe; M Mori; K Sugimachi
Journal:  Int J Colorectal Dis       Date:  1990-05       Impact factor: 2.571

9.  Arterial, portal or combined arterio-portal regional chemotherapy in experimental liver tumours?

Authors:  T Riemenschneider; C Ruf; H C Kratzsch; M Ziegler; G Späth
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

10.  Management of patients with unresectable liver metastases from colorectal and gastric cancer employing an implantable port system.

Authors:  Y Arai; T Endo; Y Sone; N Tohyama; Y Inaba; S Kohno; Y Ariyoshi; C Kido
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.